• Guido Giordano, Alessia Spagnuolo, Nunzio Olivieri, Claudia Corbo, Angelo Campagna, Ilaria Spagnoletti, Roberta Maria Pennacchio, Serena Campidoglio, Massimo Pancione, Luciano Palladino, Bruno Villari, and Antonio Febbraro.
• a Medical Oncology Unit , Ospedale Sacro Cuore di Gesù, Fatebenefratelli , Benevento , Italy.
• Expert Opin Drug Saf. 2016 Aug 1; 15 (8): 1063-74.

IntroductionBreast cancer (BC) is the most common cancer in women. Although therapeutic armamentarium like chemotherapy, endocrine and target agents have increased survival, cardiovascular side effects have been observed. A comprehensive risk assessment, early detection and management of cardiac adverse events is therefore needed.Areas CoveredIn this review we focus on cardiotoxicity data deriving from Phase III randomized trials, systematic reviews and meta-analysis in BC patients. We provide insight into advances that have been made in the molecular mechanisms, clinical presentation and management of such adverse event.Expert OpinionDespite the large number of data from Phase III trials about cardiac events incidence, there are poor evidences for detection, monitoring and management of cardiotoxicity during BC treatment. Future cardiotoxicity-oriented clinical cancer research can help to predict the risk of cardiac adverse events and improve patients' outcome. Multidisciplinary approach as well as integration of blood biomarkers with imaging will be desirable.

22 keywords...

hide…